AIMT

Aimmune Therapeutics
AIMT

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

0 hedge funds and large institutions have $0 invested in Aimmune Therapeutics in 2020 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 188 closing their positions.

New
Increased
Maintained
Reduced
Closed

less funds holding

Funds holding: →

less funds holding in top 10

Funds holding in top 10: →

less capital invested

Capital invested by funds: $ → $

less first-time investments, than exits

New positions opened: | Existing positions closed:

Holders
–
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

1
-$143M
2
-$129M
3
-$86.2M
4
Goldman Sachs
Goldman Sachs
New York
-$75.8M
5
AAM
Alpine Associates Management
Florida
-$71.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
1
–
2
–
3
–
4
–
5
–
6
–
7
–
8
–
9
–
10
–
11
–
12
–
13
–
14
–
15
–
16
–
17
–
18
–
19
–
20
–
21
–
22
–
23
–
24
–
25
–
1
2 3 4 5